SCHEMBL1673868

SCHEMBL1673868

O=C(N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O)C(Cl)(Cl)Cl

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
KDM4E B2RXH2 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C19 P33261 1/20 0.54
HK2 P52789 6/20 0.50
HK1 P19367 5/20 0.49
PYGB P11216 6/20 0.43
MAPK1 P28482 1/20 0.43
GAA P10253 1/20 0.40
ALDH1A1 P00352 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30019948 1.00 LMNA (0.54) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL1673864 1.00 LMNA (0.54) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL3966078 1.00 LMNA (0.54) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL13742863 0.84 KDM4E (0.42) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL17210624 0.84 KDM4E (0.54) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL15590477 0.84 KDM4E (0.54) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL8930010 0.84 KDM4E (0.54) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL18407097 0.84 LMNA (0.57) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL21753475 0.84 KDM4E (0.54) LMNAKDM4ECYP2D6CYP2C19HK2
SCHEMBL12371561 0.84 KDM4E (0.54) LMNAKDM4ECYP2D6CYP2C19HK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232177-B Chemical synthesis method of shigella dysenteriae 10 type O-antigen oligosaccharide 江南大学 2024-07-30 CN disclosed
CN-115232177-A Chemical synthesis method of shigella dysenteriae type 10O-antigen oligosaccharide 江南大学 2022-10-25 CN disclosed
US-20140323705-A1 MANUFACTURE OF LACTO-N-TETRAOSE GLYCOM A/S (DK) 2014-10-30 US disclosed
WO-2012155916-A1 MANUFACTURE OF LACTO-N-TETRAOSE GLYCOM A/S (DK) 2012-11-22 WO disclosed
US-20110086767-A1 MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES INSTITUT PASTEUR 2011-04-14 US disclosed
EP-2100965-A1 Mutants of glycoside hydrolases and uses thereof for synthesizing complex oligosaccharides and disaccharide intermediates Institut Pasteur (FR) 2009-09-16 EP disclosed
US-20090215710-A1 CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS RELIANCE LIFE SCIENCES PVT. LTD. (IN) 2009-08-27 US disclosed
WO-2009047792-A2 CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS RELIANCE LIFE SCIENCES PVT. LTD. (IN) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215710-A1 CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS TLR4, TLR1, TLR2 LMNA 4669/4885KDM4E 2402/4885CYP2D6 3144/4885
US-20110086767-A1 MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES ENGASE, GALE, MGAM LMNA 3194/4885KDM4E 3950/4885CYP2D6 1674/4885
US-20140323705-A1 MANUFACTURE OF LACTO-N-TETRAOSE FUT6, FUT5, ST6GAL1 LMNA 3014/4885KDM4E 3582/4885CYP2D6 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.